Steve Haycock had most of his colon removed last year but doctors have told the 43-year-old that his bowel cancer is highly likely to come back — unless a personalised vaccine trial pays off.
The product is made by German Covid-19 jab maker BioNTech, which has identified proteins specific to mutations in his cancer cells and designed a vaccine that will prime his immune system to attack new tumours containing them.
“It’s given me a lot of confidence to be on this trial,” he said. “I’m only in this position because things are going badly for me but I do feel privileged.”
您已閱讀5%（576字），剩余95%（11067字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。